文献速递冠心病血脂与心血管预防

糖尿病合并急性冠脉综合征患者的外科与经皮冠状动脉血运重建比较

Surgical Versus Percutaneous Coronary Revascularization in Patients With Diabetes and Acute Coronary Syndromes.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

基于加拿大不列颠哥伦比亚省2007至2014年人群数据库,纳入4661例接受血运重建的糖尿病患者(其中2947例为急性冠脉综合征),比较冠状动脉旁路移植术(CABG)与经皮冠状动脉介入治疗(PCI)的结局。结果显示,在急性冠脉综合征患者中,30天时CABG的主要不良心脑血管事件(MACCE)风险低于PCI,优势比为0.49(95%CI 0.34-0.71);长期(31天至5年)CABG的获益在急性冠脉综合征和稳定缺血性心脏病患者中均存在,风险比分别为0.67(95%CI 0.55-0.81)和0.55(95%CI 0.40-0.74)。

要点

  • 糖尿病合并多支病变的急性冠脉综合征患者,30天MACCE风险CABG低于PCI(OR 0.49)。
  • 长期随访中,CABG的MACCE获益在急性冠脉综合征和稳定缺血性心脏病患者中无显著交互作用。
  • 急性冠脉综合征患者长期MACCE风险CABG低于PCI(HR 0.67)。

核心结论

  • 在糖尿病合并多支冠状动脉病变患者中,无论表现为急性冠脉综合征还是稳定缺血性心脏病,CABG相对于PCI均与更低的长期MACCE发生率相关。

研究设计与样本

  • 基于加拿大不列颠哥伦比亚省大型人群数据库的回顾性队列研究,纳入2007至2014年接受冠状动脉血运重建的所有糖尿病患者共4661例,其中急性冠脉综合征患者2947例。
  • 主要终点为MACCE,包括全因死亡、非致死性心肌梗死和非致死性卒中;采用多变量调整和倾向评分模型比较CABG与PCI的风险。

主要发现

  • 血运重建后30天,急性冠脉综合征患者中CABG的MACCE优势比为0.49(95%CI 0.34-0.71),而稳定缺血性心脏病患者中血运重建策略对MACCE无影响(OR 1.46,95%CI 0.71-3.01;交互作用P<0.01)。
  • 中位随访3.3年,晚期(31天至5年)CABG相对于PCI的获益不再因就诊急缓而异,急性冠脉综合征患者MACCE的风险比为0.67(95%CI 0.55-0.81),稳定缺血性心脏病患者为0.55(95%CI 0.40-0.74;交互作用P=0.28)。

临床怎么用

  • 对于糖尿病合并多支冠状动脉病变的急性冠脉综合征患者,临床决策时可考虑CABG以降低长期MACCE风险。
  • 需结合患者具体情况和血运重建时机,个体化选择CABG或PCI。

局限性

  • 本研究为观察性研究,存在未测量混杂的可能。
  • 急性冠脉综合征患者在前瞻性随机试验中常被排除,需专门针对该人群开展CABG与PCI的随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Randomized trial data support the superiority of coronary artery bypass grafting (CABG) surgery over percutaneous coronary intervention (PCI) in diabetic patients with multivessel coronary artery disease (MV-CAD). However, whether this benefit is seen in a real-world population among subjects with stable ischemic heart disease (SIHD) and acute coronary syndromes (ACS) is unknown. OBJECTIVES: The main objective of this study was to assess the generalizability of the FREEDOM (Future REvascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multi-vessel Disease) trial in real-world practice among patients with diabetes mellitus and MV-CAD in residents of British Columbia, Canada. Additionally, the study evaluated the impact of mode of revascularization (CABG vs. PCI with drug-eluting stents) in diabetic patients with ACS and MV-CAD. METHODS: In a large population-based database from British Columbia, this study evaluated major cardiovascular outcomes in all diabetic patients who underwent coronary revascularization between 2007 and 2014 (n = 4,661, 2,947 patients with ACS). The primary endpoint (major adverse cardiac or cerebrovascular events [MACCE]) was a composite of all-cause death, nonfatal myocardial infarction, and nonfatal stroke. The risk of MACCE with CABG or PCI was compared using multivariable adjustment and a propensity score model. RESULTS: At 30-days post-revascularization, for ACS patients the odds ratio for MACCE favored CABG 0.49 (95% confidence interval [CI]: 0.34 to 0.71), whereas among SIHD patients MACCE was not affected by revascularization strategy (odds ratio: 1.46; 95% CI: 0.71 to 3.01; pinteraction <0.01). With a median follow-up of 3.3 years, the late (31-day to 5-year) benefit of CABG over PCI no longer varied by acuity of presentation, with a hazard ratio for MACCE in ACS patients of 0.67 (95% CI: 0.55 to 0.81) and the hazard ratio for SIHD patients of 0.55 (95% CI: 0.40 to 0.74; pinteraction = 0.28). CONCLUSIONS: In diabetic patients with MV-CAD, CABG was associated with a lower rate of long-term MACCE relative to PCI for both ACS and SIHD. A well-powered randomized trial of CABG versus PCI in the ACS population is warranted because these patients have been largely excluded from prior trials.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Ramanathan K, Abel JG, Park JE, et al. Surgical Versus Percutaneous Coronary Revascularization in Patients With Diabetes and Acute Coronary Syndromes. J Am Coll Cardiol. 2017. PMID: 29241487. doi:10.1016/j.jacc.2017.10.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。